Jump to main content.

Endocrine Disruptor Methods Validation Advisory Committee (EDMVAC)
Plenary Meeting - August 2, 2005

Meeting by Conference Call: 12:00 PM - 2:00 PM (EDT)

Members of the public may join this conference call in person at the conference room in the RESOLVE offices at 1255 23 rd St. NW, Suite 275, Washington, DC. To register to participate by phone, please contact Jane Smith, designated federal official for the EDMVAC, at smith.jane-scott@epa.gov or 202/564-8476.

Draft Agenda

Meeting Objectives:

12:00 - 12:05 Phoning In

12:05 - 12:10 Welcome, Introductions, Agenda Review, and Ground Rules

Objective: Review objectives of conference call, agenda, and logistics.
Format: Presentation from Jane Smith, Designated Federal Official, EPA Endocrine Disruptors Program, Dr. Gerald LeBlanc, EDMVAC Chair, and Dr. Juliana Birkhoff, RESOLVE, Facilitator.

12:10 - 12:15 EPA's Role in the Adult Male Assay

Objective: Learn about the EPA's role in validating the Adult Male Assay and associated timeline.
Format: Mr. Gary Timm and Dr. Don Bergfelt, Endocrine Disruptors Program, EPA presentation, facilitated questions and answers from EDMVAC members.

12:15 - 12:25 Industry's Role in the Adult Male Assay

Objective: Learn about industry's role in validating the Adult Male Assay.
Format: Dr. Rick Becker, American Chemistry Council, presentation.

12:25 - 1:00 Overview of the Adult Male Assay

Objective: Learn about highlights from previous studies and the basis for the study design for inter-laboratory validation.
Format: Mr. John O'Connor, DuPont, presentation.

1:00 - 1:40 Questions and Discussions

Objective: Provide commentary and advice on all aspects of the assay and the design for interlaboratory validation. Specifically:

1. Protocol optimization and transferability: Considering the number of chemicals and latest efforts that have been run in the various industrial and contract laboratories in which expected results have been documented, does the EDMVAC agree that the protocol is ready for inter-laboratory validation? If not, what additional information would be necessary to proceed?

2. Chemical selection: Considering the number and types of chemicals that have been selected to challenge the assay over several modes of action and compare with previous results, does the EDMVAC agree with the selection of the number of laboratories and chemicals for inter-laboratory validation? If not, what should be considered?

Format: Facilitated discussion among EDMVAC members, presenters and EPA.

1:40 - 1:55 Public Comment

1:55 - 2:00 Next Steps

2:00 Adjourn

Local Navigation

Jump to main content.